INTRODUCTION
Serine protease thrombin is a pivotal element of the coagulation cascade converting fibrinogen into insoluble fibrins upon endothelial cell damage and thrombosis. Zymogen prothrombin is converted to an active thrombin by products of the coagulation cascade including Factor Xa with the assistance of the cofactor Va. In addition to playing a role in blood coagulation, platelet adhesion and platelet aggregation, in recent years thrombin has been associated with occult cancer because of its ability to promote the adhesion of tumor cells to platelets and endothelial cells, the main component of angiogenesis, thereby contributing to tumor growth and metastasis (1, 2) . While it is known that thrombin generated during thrombosis including idiopathic venous thrombosis promotes malignancy in a variety of cancers, the role of thrombin in cancer cell biology remains poorly understood (2, 3) . e306 Thrombin stimulates cell growth and invasiveness of IBC from LC Laboratories, Woburn, MA, USA. SCH 79797 dihydrochloride was from Tocris Biosciences (Ellisville, MO, USA). Anti-phosphotyrosine p-Tyr (PY99) and anti-EGFR antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). p-Pak1 and vinculin monoclonal antibodies were from Sigma. Anti-Pak1 antibody was from Bethyl Laboratories, Inc. (Montgomery, TX, USA). Anti-PAR1 antibody was from Abcam (Cambridge, MA, USA).
Western blotting and immunoprecipitation
Western blot (WB) analysis and immunoprecipitation (IP) were conducted as previously described (19) . Briefly, cells were washed twice with phosphate-buffered saline (PBS) and then lysed in RIPA buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 0.5% NP40, 0.1% SDS, 0.1% sodium deoxycholate, 1x protease inhibitor cocktail [Roche Applied Science, Indianapolis, IN, USA], and phosphatase inhibitors). The cell lysates were centrifuged at 4°C for 10 minutes. The cell lysates were then resolved on an SDS-polyacrylamide gel, transferred (SDS-PAGE) to a nitrocellulose membrane, probed with the appropriate antibodies, and developed with the ECL reagent (Amersham Pharmacia Biosciences, Piscataway, NJ, USA) according to the manufacturer's instructions. For IP, lysates obtained from cells were subjected to IP with antiphosphotyrosine p-Tyr antibody, followed by incubation with protein A/G beads (Santa Cruz). After washing, the eluates from the beads were subjected to WB.
Confocal microscopy
Cells were grown on glasscover slips, fixed in 4% paraformaldehyde for 20 minutes, washed with PBS 3 times, and permeabilized in 0.1% Triton X-100 for 20 minutes. Cells were incubated with phalloidin conjugated with 488-Alexa from Molecular Probes (Eugene, OR, USA) for 30 minutes and washed with PBS 3 times. The DNA dye DAPI (Molecular Probes) was used as nuclear stain.
Cell viability assay
Cells were plated at a density of 4.0×10 3 cells/well (0.1 mL) in 96-well flat-bottomed microtiter plates and incubated overnight at 37°C. Cells were deprived of growth media for 12 hours prior to treatment. Cell viability was determined by XTT assay (Sigma) as per the instruction of the manufacturer. The percentage of cell viability of treated cells was determined by the ratio between the absorbance of treated wells and that of control wells.
Invasion assay
BD biocoat matrigel invasion chamber 24-well plate 8.0 micron (BD Biosciences; 8 μm pore size) was used. in general (9) . The stimulation of EGFR promotes cell proliferation, tumor progression, invasion, and metastasis (8) . In addition, stimulated EGFR activates MEK1 and 2, leading to cell migration and proliferation (8) . The morphological switch and cellular motility have been shown to be regulated not only by EGFR but also by p21-activated kinase (Pak1) (10) (11) (12) . Furthermore, EGFR activation also leads to Pak1 stimulation via Nck1, an adopter protein that directly interacts with EGFR and Pak1 (13) . Increased Pak1 expression and activity in human cancers, including breast cancer, is well documented (14) (15) (16) . Higher tumor grade is associated with higher levels of Pak1 protein as well as activity (14) . In addition to Pak1 overexpression, the kinase activity of Pak1, which is one of the targets of the activated Rho GTPases Cdc42 and Rac1, is also considered a marker of mammary gland tumor (16) . Pak1 targets cytoskeletal organization by regulating the formation of motile structures modulated by the small GTPases Cdc42 and Rac1 (17) . Pak1 also regulates cell metabolism, survival, differentiation, mitotic regulation, and anchorage-independent growth (18) . It is believed that breast tumor cells use various mechanisms to upregulate Pak1-mediated signaling pathways to improve survival advantage, a needed phenotypic change for acquired metastatic potential.
Until now, although the roles of thrombin in the biology of breast cancer cells including MDA-MB-231 have been investigated, there has been no study on the biology of IBC cells. Therefore, in the present study the effects of thrombin on IBC cell biology were explored. We found that thrombin not only induces morphological changes in the SUM149 cell line but also promotes the invasiveness of these cells by activating EGFR and promoting Pak1 activity. We found that either inhibiting downstream targets of thrombin such as EGFR or hindering activity of the convergent point of all pathways can inhibit SUM149 cell growth and invasion. Our study provides a rationale for developing a novel strategy to inhibit IBC cell growth and invasion, and attenuate the deleterious effects of thrombin derived from thromboembolism.
MATERIALS AND METHODS

Cell culture and reagents
The SUM149 cell line was obtained from Asterand (Detroit, MI, USA). SUM149 cells were grown in Ham's F-12 medium supplemented with 5% fetal bovine serum (Mediatech, Inc., Manassas, VA, USA), 5 μg/mL insulin (Sigma, St. Louis, MO, USA), and 1 μg/mL hydrocortisone (Sigma) in a humidified atmosphere containing 5% CO 2 at 37°C. MDA-MB-231 cells were maintained in Dulbecco's modified Eagle's medium (DMEM)-F12 (1:1) supplemented with 10% fetal bovine serum. Human thrombin was from Sigma. Erlotinib was obtained by incubation with EnVision (Dako, Carpinteria, CA, USA) for 1 hour at room temperature and visualization with liquid DAB+ substrate chromogen system (Dako). Immunostained sections were lightly counterstained with hematoxylin, dehydrated in graded ethanol, cleared in xylene, and mounted with the use of the Permount mounting medium.
RESULTS
Thrombin induces growth, invasion, and cytoskeletal organization in SUM149 cells
Previous studies have documented both inhibitory and inducible effects of thrombin on tumor cell growth, migration and invasion (1, 20) . To understand the impact of thrombin on the biology of IBC cells, we first examined the effects of thrombin on the IBC-derived cell line SUM149 and the non-IBC cell line MDA-MB-231 as a reference. We showed that thrombin induces the growth of SUM149 cells in a concentration-dependent manner, ranging from 0.125 to 0.5 U/mL (Fig. 1A) . The growth of MDA-MB-231 cells was not changed by thrombin treatment. Interestingly, we found that treatment with thrombin for 24 hours resulted in a distinct change in morphology and cytoskeletal organization such as membrane ruffling in SUM149 cells but not MDA-MB-231 cells, suggesting a dynamic effect of thrombin on the motility and invasiveness of SUM149 cells (Fig. 1B) .
Treated or nontreated cells (1×10 5 cells) were layered in the top chambers in the presence or absence of inhibitors for 12 hours. Nonmigrated cells (top chamber) were removed after the incubation period. Invaded cells were fixed in 4% paraformaldehyde and stained with DAPI for quantification. Images of random fields were captured by DP2-BSW software version 2.2 using an Olympus Inverted microscope IX71 at 10× magnification (Uplan N 10X/0.30 Ph1 UIS2) (Center Valley, PA, USA).
Pak1 kinase assay
Treated and control cell lysates (200 μg) were immunoprecipitated with anti-Pak1 antibody. Kinase assay was performed in kinase buffer (50 mM HEPES, 10 mM MgCl 2 , 2 mM MnCl 2 , 0.2 mM DTT) containing 20 μg myelin basic protein (MBP), 10 μCi of [γ-32 P] ATP, and 20 μM cold ATP. The reaction was carried out in a volume of 30 μL for 30 minutes at 30°C and then stopped by the addition of 10 μL of 4×SDS buffer. We resolved the reaction products by SDS-PAGE and analyzed the results by autoradiography.
Immunohistochemistry
Deparaffinized sections were subjected to antigen retrieval by boiling the sections in 10 mM citric acid buffer (pH 6.0) for 20 minutes. Sections were then incubated with anti-p-Pak1 antibody (1:500 dilution) or anti-PAR1 antibody (1:100 dilution) at 4°C overnight, followed cancer cells by stimulating Pak1 activity (19, 22) . Since IBC patients are often at risk of metastasis, we hypothesized that thrombin might modulate the biology of IBC cells by activating the EGFR and Pak1 pathways. As illustrated in the SUM149 and MDA-MB-231 cell lines, we found that thrombin induced Pak1 activation in the first 6 hours of treatment in SUM149 cells but not MDA-MB-231 cells (Fig. 3) . Interestingly, Pak1 protein expression levels were not altered during these periods of thrombin treatment. To independently validate the finding that thrombin promotes Pak1 activity via the EGFR pathway, thrombinstimulated SUM149 cells were exposed to erlotinib before the Pak1 activity was assayed. As shown in Figure 4A , erlotinib inclusion substantially blocked Pak1 stimulation by thrombin in SUM149 cells. Since thrombin signaling is mediated by the protease-activated receptor family, a small family of G protein-coupled namely PARs, we further assessed whether thrombin-induced Pak1 activation could be blocked or reduced by pretreating the cells with the PAR1 inhibitor SCH 79797. We found that inclusion of the PAR1 inhibitor indeed suppressed Pak1 activity (Fig.  4B) , confirming the ability of thrombin to induce Pak1 activity in IBC cells.
Thrombin induces SUM149 cell invasiveness
Since thrombin treatment of SUM149 cells was accompanied by dramatic cytoskeleton remodeling, we investigated the effect of thrombin on the invasiveness of SUM149 cells. Thrombin, at a concentration of 0.5 U/ mL, enhanced the ability of SUM149 cells to invade the
Thrombin induces EGFR phosphorylation in SUM149 cells
Since thrombin was reported to activate EGFR via protease-activated receptor-1 (PAR1) in breast carcinoma MDA-MB-231 cells (21), we next investigated whether thrombin could activate EGFR in SUM149 and MDA-MB-231 cells. In Figure 2A , the cell lysates were immunoprecipitated with p-Tyr-PY99 antibody, followed by probing with anti-EGFR antibody. The results showed that thrombin efficiently induced the activation of EGFR within 10 minutes in SUM149 cells as well as the quick activation of EGFR in MDA-MD-231 cells as shown in a previous study (21) . The thrombin-induced EGFR phosphorylation was effectively compromised by the treatment of the EGFR tyrosine kinase inhibitor erlotinib in SUM149 cells (Fig. 2B) . A previous study showed that the proliferation, migration, invasion and anchorageindependent growth of IBC SUM149 cells was inhibited by blocking the EGFR activation with erlotinib (8) . In our study we found that the inclusion of erlotinib also inhibits thrombin-induced SUM149 cell growth in a concentration-dependent manner (Fig. 2C ). Increasing the thrombin concentration from 0.125 U/mL to 0.5 U/mL shifted the IC 50 of erlotinib in SUM149 cells from 1.4 to 15 μM, suggesting that the effect of thrombin on the biology of the cells may be mediated via the EGFR pathway.
Thrombin stimulates Pak1 activity in SUM149 cells
Previous studies have demonstrated that EGFR activation is crucial for the motility and invasiveness of lower chamber of matrigel-coated transwell (Fig. 5 ). The inclusion of the PAR1 inhibitor SCH 79797 also reduced the number of invading SUM149 cells, confirming the intimate role of thrombin in the invasiveness characteristics of IBC cells. Given the essential role of EGFR in cancer cell proliferation, tumor progression, invasion, and metastasis, we hypothesized that thrombin may render its effect via the EGFR-Pak1 pathway. Using a concentration of erlotinib that does not reduce cell viability, we were able to suppress thrombin-induced SUM149 cell invasion by erlotinib. Altogether, these results establish that thrombin influences the invasive nature of IBC cells via the EGFR-Pak1 pathway.
Expression of p-Pak1 and PAR1 in IBC tissues
Although Pak1 expression levels are not altered upon thrombin treatment, high levels of activated phosphorylated Pak1 are readily induced by thrombin in the SUM149 cell line. To validate the relationship of p-Pak1 and PAR1 in IBC, we carried out a proof-of-principle study and examined a total of 13 tissues (breast: 7, skin: 3, lymph node: 3) from IBC patients using anti-p-Pak1 and anti-PAR1 antibodies an inhibitory effect of thrombin on these cells (2, 28) . Here, we report for the first time that thrombin induces proliferation and invasiveness in IBC cells through EGFR and Pak1 activation by PAR1.
Thrombin is known to transactivate EGFR in several cancer cells (21, 25, 29) . It promotes cell proliferation in colon cancer through EGFR transactivation and Src activation, and subsequently leads to PAR1-mediated ERK1/2 activation (25) . Renal carcinoma cell migration is promoted by thrombin through PAR1-mediated EGFR transactivation (29) . In breast cancer, proteolytic activation of PAR1 by thrombin promotes cell invasion by stimulating the induction of persistent transactivation of EGFR and ErbB2/HER2, and subsequently prolonged ERK1/2 signaling (21) . Since Pak1 is a component of the ERK1/2 signaling pathway (30) , which has been associated with cancer cell proliferation and invasiveness, Pak1 activation by thrombin could also mediate SUM149 cell proliferation and invasion via ERK1/2 activation, as shown here. Pak1 has been shown to be involved in the regulation of tissue factor expression in pulmonary artery ( Fig. 6A ). The immunostaining intensity matched very well between p-Pak1 and PAR1 in all IBC tissue samples. Ten of 13 tissues displayed strong nuclear immunostaining of p-Pak1 and PAR1 (the representative 5 samples, #1-#5 were shown), and moderate, weak and negative (#6) reactivities were seen in each case. p-Pak1 staining was weakly positive or negative in nonneoplastic breast ducts and stroma. PAR1 staining was strong to weak, dependent on the specimens. Since EGFR is known to be activated in IBC (8) , these results suggest that, in principle, IBC may contain a stimulated Pak1 pathway.
DISCUSSION
Accumulating evidence suggests a role of thrombin in extravascular tissues and in cancer. Many previous studies have revealed inducible effects of thrombin on the growth, migration and invasion of cancer cells including breast (1), lung (23) , gastric (24) , colon (25) , prostate (26) , and brain (27) cancer, although a few studies reported smooth muscle cells by thrombin through the signaling activation of kinases including ERK1/2 (31) .
Pak1 also regulates dynamic cytoskeletal changes required for productive cell motility and invasion by cancer cells (10) . Thrombin treatment induces prominent cytoskeletal remodeling including membrane ruffling in SUM149 cells and we have now found that Pak1 activation by thrombin might play a role in the regulation of membrane ruffling. Pak1 regulates actin reorganization through the phosphorylation of substrates including LIM kinase (32) . Further, since LIM kinase 1 activity is required for thrombin-induced microtubule destabilization and actin polymerization (17) , the activation of LIM kinase by thrombin-activated Pak1 might be involved in the cytoskeletal organization of the SUM149 cells.
Since a previous study also showed that EGFR expression was positive in 30% of patients with IBC and associated with an increased risk of IBC recurrence (33, 9) and of cancer in general (34, 35) , EGFR is believed to be a potential therapeutic target in IBC (8) . Drugs targeting EGFR have been developed for approximately 30 years. EGFR-targeting drugs including anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors have been approved for the treatment of cancer including nonsmall cell lung cancer, colorectal cancer, head and neck squamous cell carcinoma, and pancreatic cancer (36) . However, EGFR tyrosine kinase inhibitors have not shown significant clinical activity in breast cancer patients (37, 38) and no correlation has been observed between the sensitivities to EGFR tyrosine kinase inhibitors and the levels of EGFR expression in the breast cancer cell lines (39, 40) . Also, toxicities including skin toxicity, gastrointestinal toxicity, cardiac toxicity and allergic reactions are known to be associated with anti-EGFR drug treatment (41) . In addition to the primary resistance to EGFR tyrosine kinase inhibitor due to mutation in the EGFR gene or KRAS gene, acquired resistance due to a single secondary mutation T790M in EGFR exon 20 limits EGFR-targeted therapy in the case of nonsmall cell lung cancer (42) . Moreover, several molecular-designed studies have identified potential targets in the diagnosis and therapy of IBC (4, 43, 44) which are currently under development. As thrombin transactivates EGFR in cancer cells, our objective was to alter cellular malignant characteristics of IBC by inhibiting PAR1 and EGFR to impair the invasiveness of the IBC cells. For the first time, we have shown the involvement of Pak1 in cancer biological function including proliferation and invasiveness of SUM149 cells via thrombin-mediated EGFR activation (Fig. 6B) . The present study suggests that, in addition to the drugs which specifically inhibit PAR1 and EGFR, Pak1-targeted drugs might prove to be effective in IBC, either as single agents or in combination with targeted therapeutics to evolve an effective anti-IBC therapeutic strategy.
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